Background:

MAF, also named as c-Maf, belongs to the bZIP family and Maf subfamily. MAF acts as a transcriptional activator or repressor. It is involved in embryonic lens fiber cell development. MAF increases T cell susceptibility to apoptosis by interacting with MYB and decreasing BCL2 expression. Together with PAX6, it transactivates strongly the glucagon gene promoter through the G1 element. MAF activates transcription of the CD13 proximal promoter in endothelial cells. It is involved in the initial chondrocyte terminal differentiation and the disappearance of hypertrophic chondrocytes during endochondral bone development. When overexpressed, MAF represses anti-oxidant reponse element (ARE)-mediated transcription. It is involved either as an oncogene or as a tumor suppressor, depending on the cell context. A chromosomal aberration involving MAF is found in some forms of multiple myeloma (MM). Defects in MAF are the cause of cataract pulverulent juvenile-onset MAF-related (CAPJOM). Defects in MAF are the cause of cataract congenital cerulean type 4 (CCA4).

Alternative names:

MAF; Transcription factor Maf; Proto-oncogene c-Maf; V-maf musculoaponeurotic fibrosarcoma oncogene homolog

Clonality:

Polyclonal

Reactivity:

Human,Mouse,Rat

Source:

Rabbit

Isotype:

Request info at info@sobekbio.com

Immunogen:

Synthesized peptide derived from the C-terminal region of human c-Maf. at AA rangle； 270-350

Concentration:

1mg/ml

Applications:

Request info at info@sobekbio.com

Recommende dilutions:

Request info at info@sobekbio.com

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.4. Store at -20°C. Avoid repeated freeze-thaw cycles.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com